journal article
Feb 09, 2021
Clinical aspects of multiple endocrine neoplasia type 1
Topics
No keywords indexed for this article. Browse by subject →
References
164
[1]
Wermer, P. Genetic aspects of adenomatosis of endocrine glands. Am. J. Med. 16, 363–371 (1954).
10.1016/0002-9343(54)90353-8
[2]
Dreijerink, K. M. A., Goudet, P., Burgess, J. R., Valk, G. D. & International Breast Cancer in MEN1 Study Group. Breast-cancer predisposition in multiple endocrine neoplasia type 1. N. Engl. J. Med. 371, 583–584 (2014).
10.1056/nejmc1406028
[3]
Thakker, R. V. et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97, 2990–3011 (2012).
10.1210/jc.2012-1230
[4]
Carney, J. A. Familial multiple endocrine neoplasia: the first 100 years. Am. J. Surg. Pathol. 29, 254–274 (2005).
10.1097/01.pas.0000147402.95391.41
[5]
Larsson, C., Skogseid, B., Oberg, K., Nakamura, Y. & Nordenskjöld, M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332, 85–87 (1988).
10.1038/332085a0
[6]
Chandrasekharappa, S. C. et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276, 404–407 (1997).
10.1126/science.276.5311.404
[7]
Lemmens, I. et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum. Mol. Genet. 6, 1177–1183 (1997).
10.1093/hmg/6.7.1177
[8]
Goudet, P. et al. Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d’etude des tumeurs endocrines. Eur. J. Endocrinol. 165, 97–105 (2011).
10.1530/eje-10-0950
[9]
Sakurai, A. et al. Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database. Clin. Endocrinol. 76, 533–539 (2012).
10.1111/j.1365-2265.2011.04227.x
[10]
Giusti, F. et al. Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine 58, 349–359 (2017).
10.1007/s12020-017-1234-4
[11]
Stratakis, C. A. et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 85, 4776–4780 (2000).
[12]
Trump, D. et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 89, 653–669 (1996).
10.1093/qjmed/89.9.653
[13]
Romanet, P. et al. UMD-MEN1 Database: an overview of the 370 MEN1 variants present in 1676 patients from the French population. J. Clin. Endocrinol. Metab. 104, 753–764 (2019).
10.1210/jc.2018-01170
[14]
Machens, A. et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin. Endocrinol. 67, 613–622 (2007).
10.1111/j.1365-2265.2007.02934.x
[15]
Yamazaki, M. et al. Delay in the diagnosis of multiple endocrine neoplasia type 1: typical symptoms are frequently overlooked. Endocr. J. 59, 797–807 (2012).
10.1507/endocrj.ej12-0071
[16]
Goudet, P. et al. A Multiple endocrine neoplasia type-1 observatory in a French-speaking area. A tool from the Endocrine Tumor study Group (GTE). Ann. Endocrinol. 68, 154–159 (2007).
10.1016/j.ando.2006.11.003
[17]
Uchino, S. et al. Screening of the Men1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res. 60, 5553–5557 (2000).
[18]
Langer, P. et al. Prevalence of multiple endocrine neoplasia type 1 in young patients with apparently sporadic primary hyperparathyroidism or pancreaticoduodenal endocrine tumours. Br. J. Surg. 90, 1599–1603 (2003).
10.1002/bjs.4355
[19]
Skandarajah, A. et al. Should routine analysis of the MEN1 gene be performed in all patients with primary hyperparathyroidism under 40 years of age? World J. Surg. 34, 1294–1298 (2010).
10.1007/s00268-009-0388-5
[20]
Goudet, P. et al. Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D’etude des Néoplasies Endocriniennes Multiples Study Group. World J. Surg. 25, 886–890 (2001).
10.1007/s00268-001-0046-z
[21]
Goudet, P. et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’étude des Tumeurs Endocrines. J. Clin. Endocrinol. Metab. 100, 1568–1577 (2015).
10.1210/jc.2014-3659
[22]
Twigt, B. A., Scholten, A., Valk, G. D., Rinkes, I. H. M. B. & Vriens, M. R. Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up. Orphanet J. Rare Dis. 8, 50 (2013).
10.1186/1750-1172-8-50
[23]
Eller-Vainicher, C. et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J. Bone Miner. Res. 24, 1404–1410 (2009).
10.1359/jbmr.090304
[24]
Lourenço, D. M. et al. Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. J. Bone Miner. Res. 25, 2382–2391 (2010).
10.1002/jbmr.125
[25]
Burgess, J. R., David, R., Greenaway, T. M., Parameswaran, V. & Shepherd, J. J. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch. Surg. 134, 1119–1123 (1999).
10.1001/archsurg.134.10.1119
[26]
Christakis, I. et al. Parathyroid carcinoma and atypical parathyroid neoplasms in MEN1 patients: a clinico-pathologic challenge. The MD Anderson case series and review of the literature. Int. J. Surg. 31, 10–16 (2016).
10.1016/j.ijsu.2016.05.035
[27]
Singh Ospina, N., Sebo, T. J., Thompson, G. B., Clarke, B. L. & Young, W. F. Prevalence of parathyroid carcinoma in 348 patients with multiple endocrine neoplasia type 1 - case report and review of the literature. Clin. Endocrinol. 84, 244–249 (2016).
10.1111/cen.12714
[28]
Norton, J. A. et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger–Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann. Surg. 247, 501–510 (2008).
10.1097/sla.0b013e31815efda5
[29]
Marx, S. J. New concepts about familial isolated hyperparathyroidism. J. Clin. Endocrinol. Metab. 104, 4058–4066 (2019).
10.1210/jc.2018-02789
[30]
Lassen, T., Friis-Hansen, L., Rasmussen, A. K., Knigge, U. & Feldt-Rasmussen, U. Primary hyperparathyroidism in young people. When should we perform genetic testing for multiple endocrine neoplasia 1 (MEN-1)? J. Clin. Endocrinol. Metab. 99, 3983–3987 (2014).
10.1210/jc.2013-4491
[31]
Green, P. et al. High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy. Surgery 165, 124–128 (2019).
10.1016/j.surg.2018.04.064
[32]
Schreinemakers, J. M. J. et al. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J. Surg. 35, 1993–2005 (2011).
10.1007/s00268-011-1068-9
[33]
Lairmore, T. C. et al. A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 156, 1326–1334 (2014).
10.1016/j.surg.2014.08.006
[34]
Norton, J. A., Krampitz, G. & Jensen, R. T. Multiple endocrine neoplasia: genetics and clinical management. Surg. Oncol. Clin. N. Am. 24, 795–832 (2015).
10.1016/j.soc.2015.06.008
[35]
Fyrsten, E., Norlén, O., Hessman, O., Stålberg, P. & Hellman, P. Long-term surveillance of treated hyperparathyroidism for multiple endocrine neoplasia type 1: recurrence or hypoparathyroidism? World J. Surg. 40, 615–621 (2016).
10.1007/s00268-015-3297-9
[36]
Horiuchi, K. et al. Impact of ‘tailored’ parathyroidectomy for treatment of primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1. World J. Surg. 42, 1772–1778 (2018).
10.1007/s00268-017-4366-z
[37]
Tonelli, F., Marcucci, T., Giudici, F., Falchetti, A. & Brandi, M. L. Surgical approach in hereditary hyperparathyroidism. Endocr. J. 56, 827–841 (2009).
10.1507/endocrj.k09e-204
[38]
Iacobone, M., Carnaille, B., Palazzo, F. F. & Vriens, M. Hereditary hyperparathyroidism—a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch. Surg. 400, 867–886 (2015).
10.1007/s00423-015-1342-7
[39]
Kluijfhout, W. P. et al. Unilateral Clearance for primary hyperparathyroidism in selected patients with multiple endocrine neoplasia type 1. World J. Surg. 40, 2964–2969 (2016).
10.1007/s00268-016-3624-9
[40]
Manoharan, J. et al. Single gland excision for MEN1-associated primary hyperparathyroidism. Clin. Endocrinol. 92, 63–70 (2020).
10.1111/cen.14112
[41]
Montenegro, F. L. de M. et al. Could the less-than subtotal parathyroidectomy be an option for treating young patients with multiple endocrine neoplasia type 1-related hyperparathyroidism? Front. Endocrinol. 10, 123 (2019).
10.3389/fendo.2019.00123
[42]
Filopanti, M. et al. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Eur. J. Endocrinol. 167, 157–164 (2012).
10.1530/eje-12-0117
[43]
Giusti, F. et al. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to multiple endocrine neoplasia syndrome type 1 (MEN1). Endocrine 52, 495–506 (2016).
10.1007/s12020-015-0696-5
[44]
Donegan, D. et al. Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. Clin. Endocrinol. 86, 199–206 (2017).
10.1111/cen.13264
[45]
van Asselt, S. J. et al. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointest. Endosc. 81, 159–167 (2015).
10.1016/j.gie.2014.09.037
[46]
Barbe, C. et al. Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig. Liver Dis. 44, 228–234 (2012).
10.1016/j.dld.2011.09.014
[47]
Yates, C. J., Newey, P. J. & Thakker, R. V. Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. Lancet Diabetes Endocrinol. 3, 895–905 (2015).
10.1016/s2213-8587(15)00043-1
[48]
Anlauf, M. et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am. J. Surg. Pathol. 30, 560–574 (2006).
10.1097/01.pas.0000194044.01104.25
[49]
Jensen, R. T., Berna, M. J., Bingham, D. B. & Norton, J. A. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 113, 1807–1843 (2008).
10.1002/cncr.23648
[50]
Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients
Pierre Goudet, Arnaud Murat, Christine Binquet et al.
Molecular Medicine
2010
10.1007/s00268-009-0290-1
Showing 50 of 164 references
Cited By
120
Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review
The Journal of Clinical Endocrinolo...
Benjamin Chevalier, Lucie Coppin · 2024
Hereditary Primary Hyperparathyroidism
Endocrinology and Metabolism Clinic...
Paul J. Newey · 2021
Metrics
120
Citations
164
References
Details
- Published
- Feb 09, 2021
- Vol/Issue
- 17(4)
- Pages
- 207-224
- License
- View
Authors
Cite This Article
Abdallah Al-Salameh, Guillaume Cadiot, Alain Calender, et al. (2021). Clinical aspects of multiple endocrine neoplasia type 1. Nature Reviews Endocrinology, 17(4), 207-224. https://doi.org/10.1038/s41574-021-00468-3
Related
You May Also Like
Inflammaging: a new immune–metabolic viewpoint for age-related diseases
Claudio Franceschi, Paolo Garagnani · 2018
2,775 citations
Short-chain fatty acids in control of body weight and insulin sensitivity
Emanuel E. Canfora, Johan W. Jocken · 2015
1,908 citations
Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment
Hector F. Escobar-Morreale · 2018
1,573 citations